Drugs / LY2624587
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01139788 | Jun 2010 → Nov 2011 | metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2624587 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01139788 ↗ |
| Route | Intravenous | “administered intravenously” NCT01139788 ↗ |